Acupuncture of different treatment frequency in postprandial distress syndrome: A pilot randomized clinical trial

Neurogastroenterol Motil. 2020 Jun;32(6):e13812. doi: 10.1111/nmo.13812. Epub 2020 Feb 12.

Abstract

Background: The evidence for different frequencies of acupuncture treatment in postprandial distress syndrome (PDS) is insufficient. This study determined whether 3 sessions per week of acupuncture treatment are superior to 1 session per week for symptomatic outcomes in PDS.

Methods: This 16-week randomized clinical pilot trial was conducted in an outpatient setting in China. Patients with PDS were randomly assigned to receive 3 sessions per week of acupuncture (group H) or 1 session per week of acupuncture (group L) for 4 weeks. The primary outcome was the complete elimination of core symptoms at week 4. Secondary outcomes included overall treatment efficacy, dyspepsia symptoms, quality of life, anxiety, and depression.

Key results: Sixty patients were randomized of whom 53 (88.3%) completed this trial. The complete elimination rate of core symptoms was 26.7% (95% CI 12.3%-45.9%) in group H and 10.0% (95% CI 2.1%-26.5%) in group L at week 4 (P = .095). There was a significant difference between H and group L at weeks 8, 12, and 16 (P = .038, .02, and .02). All secondary outcomes were better in group H at all time points. No serious adverse events occurred in either groups.

Conclusions: This trial showed that acupuncture, at 3 sessions per week, tended to improve symptoms and the quality of life among patients with PDS as compared to once a week. Acupuncture treatment for 4 weeks was feasible and safe. A larger sample, multicenter, randomized controlled trial of acupuncture for PDS appears to be justified in the future.

Keywords: acupuncture; functional dyspepsia; postprandial distress syndrome; randomized controlled trial; treatment frequency.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acupuncture Therapy / methods*
  • Adult
  • Dyspepsia / therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Postprandial Period
  • Prospective Studies
  • Quality of Life
  • Treatment Outcome

Associated data

  • ChiCTR/ChiCTR1800019127